LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Regulus shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The investigation concerns whether Regulus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 27, 2016, Regulus detailed that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug to treat it chronic hepatitis C virus infection which was under FDA review, will now be put under clinical hold following a second intense case of jaundice.
On January 27, 2017, post-market, Regulus revealed that the FDA would not reconsider the clinical hold on RG-101 until the agency had received the last safety and efficacy data from continued clinical and pre-clinical studies. Regulus informed shareholders that it expects the required data to be available in the fourth quarter of 2017.
When this information was revealed to the investing public, the value of Regulus declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.